Antibodies to glutaraldehyde-polymerized human albumin (anti-pHSA) in viral hepatitis

The antibody to polymerized human albumin (anti-pHSA) was studied in normal subjects and in the course of infection from hepatitis A virus, hepatitis B virus, and hepatitis non-A, non-B virus. Results show that anti-pHSA antibody was never found in normal subjects, but it appeared during virus liver pathologies. The behavior of anti-pHSA differs in acute type A hepatitis that does not change to chronic form and in those forms which tend to become chronic (B and nonA, nonB). In the type-A infection anti-pHSA disappears after the acute phase; in the other two forms it persists all along as the infection develops. Specifically in non-A, non-B infection only the IgM type anti-pHSA is produced.

Correlation between hepatitis B virus deoxyribonucleic acid and receptors for polymerized human albumin in HBV chronic infection

This study indicates that hepatitis B virus deoxyribonucleic acid (HBV DNA) is actually the most sensitive marker for the identification of HBV-related pathologies in active replication phase and does not correlate with serum receptor activity for polymerized human serum albumin which can be found in absence of either HBV DNA or HBeAg in HBV chronic infection.

Detection of receptors for polymerised human albumin by immunoperoxidase and immunoadherence in liver tissue of HBsAg chronic carriers

Receptors for polymerised human albumin (pHSA-Rs) were detected in unfixed cryostat sections from HBsAg chronic carriers using direct immunoperoxidase and immunoadherence methods. Although pHSA-Rs were detected by both methods, the receptors detected by immunoperoxidase were associated with HBV and showed properties different from the receptors detected by immunoadherence. The double immunocytochemical staining which detected contemporaneously pHSA-Rs and HBsAg in the same cell showed that there are two types of infected hepatocytes: one capable of synthesizing pHSA-Rs and HBsAg and the other capable of synthesizing only HBsAg. The intrahepatocyte synthesis of pHSA-Rs does not correlate with the severity of chronic liver disease or with the presence of tissue HB core antigen.

Demonstration of HBsAg as the antigen component in circulating immune complexes detected by peg-solid phase test

The development of an enzyme-linked immunosorbent assay to identify HBsAg as the antigen component within circulating immune complexes using immobilized polyethylene glycol (PEG) is described. The method utilizes, on one hand, the ability of PEG to bind stably to plastic supports and, on the other, to precipitate circulating macromolecules. This method is easily performed, very cheap, quick and, above all, it helps define the biological nature of the immune complexes. HBsAg can be revealed as the antigen component of HBsAg/anti-HBs soluble immune complexes at concentrations of at least 20 ng/ml and either in antigen or antibody excess. Our results indicate that HBsAg circulates in a complexed form in 47% of HBsAg chronic carriers and in 10.7% of patients with liver disease who are positive for serum antibody to hepatitis B surface antigen (anti-HBs) and to core antigen (anti-HBc). None of the other groups of patients in the study had circulating HBsAg in the complexed form.

Binding and receptors for human albumin polymers and IgM/HBs circulating complex in HBsAg chronic carriers

Binding activity for polymerized human serum albumin (pHSA-binding), studied in passive haemoagglutination, receptors for polymerized human serum albumin (pHSA-receptors), studied in ELISA, as well as the circulating IgM/HBs complex were tested in 71 chronic carriers of HBsAg with and without liver pathology. We found that 73.2% of the sera were reactive for pHSA-binding while 45% were reactive for pHSA-receptors and 42.2% for the circulating IgM/HBs complex. The distribution and mode of association of these 3 markers showed a close correlation with the e-antigen in circulation (HBeAg) and with liver disease (p less than 0.05). We further observed that pHSA-binding can be present in the absence of pHSA-receptors, suggesting the possible existence of further reactants in the serum-pHSA reaction. We did not observe any correlations between the circulating IgM/HBs complexes, pHSA-binding and pHSA-receptors. Blocking experiments, in fact, confirmed the non-involvement of polymerized human serum albumin in the formation of the circulating IgM/HBs complex. Elution experiments showed that, in addition to HBsAg, class-G immunoglobulins are also directly involved in the serum-pHSA reaction.